» Cara Therapeutics Announces Successful Completion Of Phase I Clinical Trial Of Novel Analgesic, CR845
Cara Therapeutics, Inc. announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and…